GlaxoSmithKline Pharmaceuticals Limited has announced its financial results for the second quarter ended 30th June 2009.
The Company has posted a Net Sales growth of 10% compared to the previous quarter, while Profit Before Tax has grown by 17%, on a comparable basis.
Commenting on the performance during the quarter, Dr. Hasit B. Joshipura, Managing Director, said, ?The Company?s products during the quarter have achieved market competitive growth. Recent new launches including Arixtra, the antithrombotic agent, Rotarix, the rotavirus diarrhea vaccine and Tykerb for refractory breast cancer are all tracking ahead of plan?.